IGF1 and prostate carcinoma: Prostate cancer DTCs utilise signalling from growth factors such as transforming growth factor beta (TGF-β) and insulin-like growth factor 1 (IGF-1), which are liberated by osteoblastic and osteoclastic remodelling of the bone, to support their proliferation, survival, and subsequent colonisation [162,168,169].